Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Immuneering Co. (NASDAQ:IMRX) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $13.50.

A number of equities analysts recently issued reports on IMRX shares. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $25.00 price objective on shares of Immuneering in a research note on Tuesday, March 5th. Mizuho lowered their target price on Immuneering from $20.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Chardan Capital reduced their price target on Immuneering from $21.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, March 15th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $3.00 price objective (down from $16.00) on shares of Immuneering in a research report on Friday, March 15th.

Insider Transactions at Immuneering

In other news, major shareholder Cormorant Asset Management, Lp sold 509,091 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $3.72, for a total transaction of $1,893,818.52. Following the completion of the transaction, the insider now owns 3,695,273 shares in the company, valued at $13,746,415.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Immuneering news, Director Ann E. Berman acquired 57,965 shares of the stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $2.13 per share, for a total transaction of $123,465.45. Following the completion of the transaction, the director now directly owns 67,465 shares of the company’s stock, valued at $143,700.45. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Cormorant Asset Management, Lp sold 509,091 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $3.72, for a total transaction of $1,893,818.52. Following the completion of the sale, the insider now owns 3,695,273 shares in the company, valued at $13,746,415.56. The disclosure for this sale can be found here. Insiders acquired a total of 111,790 shares of company stock valued at $266,645 over the last 90 days. Company insiders own 25.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in IMRX. Exchange Traded Concepts LLC raised its position in Immuneering by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 17,416 shares of the company’s stock valued at $128,000 after purchasing an additional 4,417 shares during the period. Southport Management L.L.C. purchased a new stake in Immuneering during the 3rd quarter valued at $134,000. Corton Capital Inc. bought a new stake in Immuneering in the third quarter worth $145,000. PNC Financial Services Group Inc. purchased a new position in Immuneering during the third quarter worth $154,000. Finally, Adage Capital Partners GP L.L.C. increased its position in Immuneering by 11.4% during the third quarter. Adage Capital Partners GP L.L.C. now owns 195,000 shares of the company’s stock valued at $1,498,000 after acquiring an additional 20,000 shares during the last quarter. Institutional investors own 67.65% of the company’s stock.

Immuneering Price Performance

NASDAQ IMRX opened at $1.63 on Friday. The stock has a market capitalization of $48.33 million, a price-to-earnings ratio of -0.86 and a beta of -0.60. Immuneering has a 1-year low of $1.38 and a 1-year high of $11.92. The business’s fifty day moving average price is $3.00 and its 200-day moving average price is $5.28.

Immuneering (NASDAQ:IMRX) last posted its earnings results on Friday, March 1st. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.06). Equities research analysts anticipate that Immuneering will post -1.89 EPS for the current year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.